Teva Pharmaceutical Industries Ltd. ADR (TEVA)
Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid
TEVA's latest bid for BioXcel assets could expand its neuroscience portfolio with Igalmi and a potential at-home agitation treatment.
TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome
Teva's ecopipam secures FDA priority review for pediatric Tourette syndrome, potentially bringing the first new therapy in over a decade.
Teva Rises 17% YTD: Should You Buy, Sell or Hold the Stock?
Teva's stock gains reflect stronger branded drug growth, a strengthening pipeline and improving finances, but generics and debt remain key risks.
Teva's Re-Rating Still Has Room To Run
Teva Pharmaceutical is undergoing a transformation, shifting its revenue mix toward specialty and innovative drugs, now over $1 billion per quarter. TEVA targets $3.7 billion in specialty/innovative sales for 2026 and aims for operating margins near 30% by 2027, driven by product mix and cost savings. Leverage has dropped below 3x EBITDA, with a goal of 2x by 2027, supported by $2–$2.4 billion free cash flow guidance for 2026.
Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock Rises
TEVA misses Q2 earnings estimates as Emalex acquisition costs weigh on profits, while innovative drugs drive a revenue beat and an increased 2026 sales outlook.
Teva Pharmaceutical Industries Q2 Earnings Call Highlights
Teva Pharmaceutical Industries NYSE: TEVA reported second-quarter 2026 revenue of approximately $4.1 billion, down 1% from a year earlier in U.S. dollars, as lower sales from generic Revlimid were largely offset by growth in its innovative medicines portfolio.
Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 Earnings Call Transcript
Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Stay Ahead of the Game With Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street's Insights on Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Teva Pharmaceutical Industries (TEVA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Teva Pharmaceutical Industries' Anti-IL-15 Antibody Shows Promise in Vitiligo Study
Teva Pharmaceutical Industries NYSE: TEVA said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the company highlighted the program as part of its broader shift toward a biopharma-focused growth strategy.
Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b Transcript
Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b Transcript
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.
